Form 4: Immunovant Director Atul Pande Reports Acquisition of Shares and Stock Options

Director Atul Pande reported acquiring shares and stock options in Immunovant, Inc. on April 2, 2024.

Summary

• On April 2, 2024, Atul Pande, a director of Immunovant, Inc., reported acquiring 11,255 shares of common stock and 4,690 stock options.
• The shares were acquired at a price of $0.
• These restricted stock units (RSUs) were granted pursuant to the Issuer's 2019 Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit.
• The RSUs will vest in full on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date.
• The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
• The shares underlying the options will vest on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date.
• Following the transaction, Pande directly owns 94,413 shares of common stock and indirectly owns 20,000 shares through a trust.
• He also directly owns 4,690 stock options with an exercise price of $30.78, expiring on April 2, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing transactions by an insider. The acquisition of shares and options could be seen as mildly positive, but it's not a strong indicator.

Positives

• The acquisition of shares and stock options by a director could be interpreted as a positive signal about the director's confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the reporting person's continuous service to the issuer, suggesting an incentive for continued involvement with the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The reported transactions may influence investor sentiment regarding Immunovant's stock.

Key Dates